Profusa Inc

PFSA

Market cap $551K

BERKELEY, Calif., July 27, 2026 (GLOBE NEWSWIRE) --  Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of a non-binding term sheet with a privately held, commercial-stage health diagnostics and toxicology testing company (the "Dx Company").

BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-twenty-five (1:25) reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on July 7, 2026, and the Company's common stock will open for trading on The Nasdaq Global Market on July 7, 2026 on a post-split basis, under the existing ticker symbol “PFSA” but with a new CUSIP number 74319X 306.

BERKELEY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces that shareholders approved all proposals presented at the Company's 2026 Annual Meeting of Shareholders held on June 23, 2026.

BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its response package to questions received from its European Notified Body, GMED, following the successful completion of the Stage 1 and Stage 2 quality system and technical documentation assessments conducted by GMED as part of the MDR conformity assessment process for the Lumee® Oxygen Platform.

BERKELEY, CA, June 10, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a leading digital health company pioneering next-generation biosensing technologies, today issued the following letter from Chairman and Chief Executive Officer Ben Hwang, Ph.D., to shareholders in advance of the Company's 2026 Annual Meeting of Shareholders scheduled for June 23, 2026.

BERKELEY, CA, May 15, 2026 (GLOBE NEWSWIRE) --  Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a  digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces  that, effective May 15, 2026, the Company will now be listed on The Nasdaq Capital Market.  The move is the first of a previously announced series of interim milestones as laid out by the Nasdaq Hearings Panel to ensure continued compliance with the bid price and stockholders' equity requirements for continued listing on the Capital Market tier.

BERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a  digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announced that, by letter dated May 6, 2026, the Nasdaq Hearings Panel granted the Company's request to transfer the listing of its securities from The Nasdaq Global Market to The Nasdaq Capital Market. The Company's continued listing on Nasdaq is subject to the Company's satisfaction of certain interim milestones and, ultimately, the Company's compliance with the bid price and stockholders' equity requirements for continued listing on the Capital Market tier by July 6, 2026.

Company focusing resources on near-term commercial milestones; European CE Mark process and Healthcare Research revenue opportunities Process intended to evaluate strategic growth alternatives to enhance scale, strengthen execution and support long-term shareholder value creation BERKELEY, CA, May 05, 2026 (GLOBE NEWSWIRE) --  Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announced that its Board of Directors has initiated a Board-led process to evaluate strategic alternatives intended to maximize shareholder value and support the Company's highest-priority commercial, regulatory and platform-expansion initiatives. The process will evaluate a range of potential opportunities, including asset-level transactions, commercial and strategic partnerships, business combinations and other corporate transactions.

Company secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications BERKELEY, CA, April 06, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, today announced a strategic expansion into molecular diagnostics through a Letter of Intent to acquire the PanOmics™ multi-omics diagnostics platform from BioInsights LLC (“BioInsights”).  The Company believes this acquisition, adding to its core real-time biochemistry monitoring platform, will help to position Profusa at the intersection of biosensing, diagnostics, and precision medicine, establishing a foundation for scalable multi-product diagnostics and monitoring franchise.

After Reevaluating its Near-term Capital Needs Given the Recent Changes in its Projected 2026 Revenue and Mayo Collaboration, the Company Determined that a $15 Million Offering is Not Required to Achieve Near-term Revenue Projections